Genetic testing, powered for prostate cancer

Improve outcomes with genetic testing


The National Comprehensive Cancer Network® (NCCN®) recommends all patients with metastatic prostate cancer undergo BRCA1/BRCA2 genetic testing.1

According to a recent NEJM study:2

  • >11%  of men with metastatic prostate cancer have an inherited mutation
  • Genetic status impacts treatment decisions
  • Family history alone cannot reliably predict an inherited DNA-repair defect that may have risk of disease associated with metastatic prostate cancer

Who should be considered for genetic testing?

This panel may be appropriate if your patient or their family members have any of the following:

  • Metastatic prostate cancer
  • Gleason score ≥7 and a family history of breast, ovarian, pancreatic or prostate cancer
  • Rare cancers including male breast cancer or ovarian cancer
  • Cancer diagnosed at a young age (<50 years)
  • Multiple cancers (e.g., 2+ primary cancers in the same person or 3+ ­­­diagnoses on the same side of the family)
  • A known pathogenic genetic variant in the family

Genetic status impacts treatment decisions

Results from the Invitae Prostate Cancer Panel can help guide medical management, including:2

  • PARP inhibitors
  • Platinum agents
  • Immunotherapy

Invitae Prostate Cancer Panel

Invitae offers comprehensive genetic testing for patients at risk for hereditary prostate cancer. More than 180,000 cases of prostate cancer are diagnosed each year; 5-10% of those are expected to be hereditary.2,3

Pathogenic variants in BRCA1 and BRCA2 are only part of the story. Invitae’s comprehensive prostate cancer panel targets up to 14 genes that evidence associates with a hereditary predisposition to prostate cancer:

ATM,  BRCA1,  BRCA2,  CHEK2,  EPCAM,  HOXB13,  MLH1,  MSH2,  MSH6,  NBN,  PALB2,  PMS2,  RAD51D,  TP53

Results are available in 10–21 calendar days (14 days on average).


Invitae makes genetic testing easy

Support for you

Genetic counselors available to review cases and aid in interpreting results

Learn more

Support for patients

Genetic counselors on-hand to speak with your patients at no additional charge

Learn more

Test family members

Positive result? Test first-degree relatives at no additional charge within 90 days

Learn more

Simple pricing. Simple billing. No surprises.

  • Invitae is dedicated to accessible pricing, with no explanation of benefits >$1500 ever
  • Medicare and Medicaid accepted and Patient Assistance Program available to patients who meet the clinical and income criteria

A positive result has implications not only for treatment, but also for future cancer risk

Lifetime cancer risks for prostate cancer genes

1Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast and Ovarian V.1.2018. ©National Comprehensive Cancer Network, Inc 2016. All rights reserved. Accessed October 10, 2017. To view the most recent and complete version of the guideline, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
2Pritchard, CC. et al. NEJM, 2016.
3Cancer Genome Atlas Research Network. Cell, 2015.
4Nicolosi, PLW et al. Presented at ASCO Annual Meeting; June 2017; Chicago, Illinois.